Literature DB >> 11111019

Metabolism of glucagon by dipeptidyl peptidase IV (CD26).

J A Pospisilik1, S A Hinke, R A Pederson, T Hoffmann, F Rosche, D Schlenzig, K Glund, U Heiser, C H McIntosh, H Demuth.   

Abstract

Glucagon is a 29-amino acid polypeptide released from pancreatic islet alpha-cells that acts to maintain euglycemia by stimulating hepatic glycogenolysis and gluconeogenesis. Despite its importance, there remains controversy about the mechanisms responsible for glucagon clearance in the body. In the current study, enzymatic metabolism of glucagon was assessed using sensitive mass spectrometric techniques to identify the molecular products. Incubation of glucagon with purified porcine dipeptidyl peptidase IV (DP IV) yielded sequential production of glucagon(3-29) and glucagon(5-29). In human serum, degradation to glucagon(3-29) was rapidly followed by N-terminal cyclization of glucagon, preventing further DP IV-mediated hydrolysis. Bioassay of glucagon, following incubation with purified DP IV or normal rat serum demonstrated a significant loss of hyperglycemic activity, while a similar incubation in DP IV-deficient rat serum did not show any loss of glucagon bioactivity. Degradation, monitored by mass spectrometry and bioassay, was blocked by the specific DP IV inhibitor, isoleucyl thiazolidine. These results identify DP IV as a primary enzyme involved in the degradation and inactivation of glucagon. These findings have important implications for the determination of glucagon levels in human plasma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11111019     DOI: 10.1016/s0167-0115(00)00170-1

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  12 in total

1.  Co-expression of the homologous proteases fibroblast activation protein and dipeptidyl peptidase-IV in the adult human Langerhans islets.

Authors:  Petr Busek; Petr Hrabal; Premysl Fric; Aleksi Sedo
Journal:  Histochem Cell Biol       Date:  2014-11-02       Impact factor: 4.304

2.  Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury.

Authors:  Elliot J Glotfelty; Thomas Delgado; Luis B Tovar-Y-Romo; Yu Luo; Barry Hoffer; Lars Olson; Tobias Karlsson; Mark P Mattson; Brandon Harvey; David Tweedie; Yazhou Li; Nigel H Greig
Journal:  ACS Pharmacol Transl Sci       Date:  2019-02-11

Review 3.  Novel insight into glucagon receptor action: lessons from knockout and transgenic mouse models.

Authors:  P M Vuguin; M J Charron
Journal:  Diabetes Obes Metab       Date:  2011-10       Impact factor: 6.577

4.  The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism.

Authors:  Michael Engel; Torsten Hoffmann; Leona Wagner; Michael Wermann; Ulrich Heiser; Reiner Kiefersauer; Robert Huber; Wolfram Bode; Hans-Ulrich Demuth; Hans Brandstetter
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-10       Impact factor: 11.205

5.  DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus.

Authors:  W Wang; X Wen; W Duan; X Wang; Y Chen; J Dong; Z Yang; J Fang; Z Zhou; G Yao; Y Fang; Y Huang
Journal:  J Endocrinol Invest       Date:  2019-11-30       Impact factor: 4.256

6.  A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.

Authors:  Victor A Gault; Vikas K Bhat; Nigel Irwin; Peter R Flatt
Journal:  J Biol Chem       Date:  2013-10-28       Impact factor: 5.157

7.  A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents.

Authors:  K Tatarkiewicz; D M Hargrove; C M Jodka; B R Gedulin; P A Smith; J A Hoyt; A Lwin; L Collins; L Mamedova; O E Levy; L D'Souza; S Janssen; V Srivastava; S S Ghosh; D G Parkes
Journal:  Diabetes Obes Metab       Date:  2013-08-19       Impact factor: 6.577

8.  Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.

Authors:  Tsuyoshi Yanagimachi; Yukihiro Fujita; Yasutaka Takeda; Jun Honjo; Hidemitsu Sakagami; Hiroya Kitsunai; Yumi Takiyama; Atsuko Abiko; Yuichi Makino; Timothy J Kieffer; Masakazu Haneda
Journal:  Mol Metab       Date:  2016-12-31       Impact factor: 7.422

9.  Relationship Between Fasting Plasma Glucagon Level and Renal Function-A Cross-Sectional Study in Individuals With Type 2 Diabetes.

Authors:  Jian-Jun Liu; Sylvia Liu; Resham L Gurung; Clara Chan; Keven Ang; Wern Ee Tang; Subramaniam Tavintharan; Chee Fang Sum; Su Chi Lim
Journal:  J Endocr Soc       Date:  2018-12-03

Review 10.  Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors.

Authors:  Erin E Mulvihill; Daniel J Drucker
Journal:  Endocr Rev       Date:  2014-09-12       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.